Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab

摘要

Background and Aims: Vedolizumab is an IgG1 anti-alpha 4 beta 7 integrin antibody approved for the treatment of inflammatory bowel diseases[IBD], but without clear safety data during conception, pregnancy and nursing. Animal studies showed that mucosal vascular addressin cell adhesion molecule 1[MAdCAM-1] is expressed by maternal vessels in the placenta and recruits alpha 4 beta 7-expressing cells that are considered important for maternal/fetal tolerance. Blocking this interaction by vedolizumab might affect this process. We aimed to evaluate pregnancy outcomes in vedolizumab-treated female IBD patients.